Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2019 | Next steps for CAR-T in ALL

Stephan Grupp • 7 Dec 2019
ASH 2019
Acute Lymphoblastic Leukemia Leukemia CAR-T

Stephan Grupp, MD, PhD, Children’s Hospital of Philadelphia, Philadelphia, PA, shares his opinion on what should now be the focus of CAR-T research in acute lymphoblastic leukemia (ALL). Dr Grupp highlights the need for longer follow-ups, extending the reach of CAR-T therapies, and improvements in manufacturing. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.

More from Stephan Grupp

1:33
Patient selection for CAR-T in ALL
Stephan Grupp • 2 Sep 2021
2:16
The latest research in ALL cellular therapy
Stephan Grupp • 2 Sep 2021
1:21
The future of treating pediatric ALL with CAR-T
Stephan Grupp • 2 Sep 2021
0:57
The importance of common language for CAR-T
Stephan Grupp • 18 Mar 2021

Related Videos

2:06
Managing relapsed ALL: the role of novel cellular therapies & importance of conditioning regimens
Christina Peters • 15 Apr 2024
1:14
Promising novel agents in AML: menin inhibitors
Mark Levis • 16 Apr 2024
3:02
EUPLAGIA-1: Phase I trial of GLPG5201, a CD19 CAR-T product, in R/R CLL and Richter's transformation
Valentin Ortiz-Maldonado • 16 Apr 2024
1:48
Do all patients require maintenance therapy following alloSCT?
Mark Levis • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals